AR103182A1 - Inmunomoduladores - Google Patents
InmunomoduladoresInfo
- Publication number
- AR103182A1 AR103182A1 ARP150104203A ARP150104203A AR103182A1 AR 103182 A1 AR103182 A1 AR 103182A1 AR P150104203 A ARP150104203 A AR P150104203A AR P150104203 A ARP150104203 A AR P150104203A AR 103182 A1 AR103182 A1 AR 103182A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- hydrogen
- methyl
- independently selected
- optionally substituted
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 19
- 239000001257 hydrogen Substances 0.000 abstract 17
- 229910052739 hydrogen Inorganic materials 0.000 abstract 17
- -1 amino, hydroxy Chemical group 0.000 abstract 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 7
- 125000004429 atom Chemical group 0.000 abstract 5
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 5
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 101100240521 Caenorhabditis elegans nhr-16 gene Proteins 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000006916 protein interaction Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Proporciona péptidos macrocíclicos que inhiben las interacciones proteína/proteína PPD-1/PD-L1 y PD-L1/CD80, y por ende, son útiles para la mejora de varias enfermedades, que incluyen el cáncer y las enfermedades infecciosas. Reivindicación 1: Un compuesto, caracterizado porque tiene la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico, en donde: A se selecciona de un enlace, o un compuesto del grupo de fórmulas (2); en donde: la línea ondulada * indica el punto de unión al grupo carbonilo y la línea ondulada indica el punto de unión al átomo de nitrógeno; z es 0, 1 ó 2; w es 1 ó 2; n es 0 ó 1; m es 1 ó 2; m es 0 ó 1; p es 0, 1 ó 2; Rˣ se selecciona de hidrógeno, amino, hidroxi y metilo; R¹⁴ y R¹⁵ se seleccionan independientemente de hidrógeno y metilo; y Rᶻ se selecciona de hidrógeno y -C(O)NHR¹⁶; en donde R¹⁶ se selecciona de hidrógeno, -CHR¹⁷C(O)NH₂, -CHR¹⁷C(O)NHCHR¹⁸C(O)NH₂ y -CHR¹⁷C(O)NHCHR¹⁸C(O)NHCH₂C(O)NH₂; en donde R¹⁷ se selecciona de hidrógeno y -CH₂OH, y en donde R¹⁸ se selecciona de hidrógeno y metilo; Rᵛ es hidrógeno o una cadena lateral de aminoácido natural; Rᶜ, Rᶠ, Rʰ, Rⁱ y Rᵐ son hidrógeno; Rⁿ es hidrógeno o metilo, o Rᵛ y Rⁿ forman un anillo de pirrolidina; Rᵃ, Rᵉ, Rʲ y Rᵏ se seleccionan independientemente de hidrógeno y metilo; cada R²⁰ se selecciona independientemente de hidrógeno y C₁₋₆alquilo; cada R²¹ se selecciona independientemente de hidrógeno y C₁₋₆alquilo; R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² y R¹³ se seleccionan independientemente de una cadena lateral de aminoácido natural y una cadena lateral de aminoácido no natural, o cada uno puede formar independientemente un anillo carbocíclico de tres a seis miembros o un anillo de seis miembros que contiene un átomo de oxígeno o de nitrógeno con un grupo R²⁰ germinal correspondiente, en donde el anillo se sustituye opcionalmente con uno, dos o tres sustituyentes seleccionados independientemente de C₁₋₃alcoxi, C₁₋₃alquilo, C₂₋₄alquenilo, halo, hidroxi y amino y en donde el anillo de cinco y seis miembros se fusiona opcionalmente a un anillo de fenilo; o R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² y R¹³ pueden formar, cada uno independientemente, un anillo con el grupo R próximo correspondiente como se describe más adelante; Rᵉ y Rᵏ pueden formar, cada uno, un anillo con el grupo R próximo correspondiente y los átomos a los que están unidos, seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; Rᵇ es metilo, o Rᵇ y R², junto con los átomos a los que están unidos, forman un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; o cuando R² y el R²⁰ germinal no son hidrógeno, Rᵇ es hidrógeno; Rᵈ es hidrógeno o metilo, o Rᵈ y R⁴, junto con los átomos a los que están unidos, pueden formar un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo, hidroxi y fenilo; Rᵍ es hidrógeno o metilo, o Rᵍ y R⁷, junto con los átomos a los que están unidos, pueden formar un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, bencilo opcionalmente sustituido con un grupo halo, bencìloxi, ciano, ciclohexilo, metilo, halo, hidroxi, isoquinoliniloxi opcionalmente sustituido con un grupo metoxi, quinoliniloxi opcionalmente sustituido con un grupo halo, y tetrazolilo; y en donde los anillos de pirrolidina y piperidina están opcionalmente fusionados con un grupo ciclohexilo, fenilo o indol; y Rˡ es metilo, o Rˡ y R¹², junto con los átomos a los que están unidos, forman un anillo seleccionado de azetidina y pirrolidina, en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; siempre que el compuesto de la fórmula (1) contenga al menos un carbono en la estructura principal del anillo que tiene cuatro sustituyentes que no son hidrógeno y no es un anillo sustituido con a-metilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462094281P | 2014-12-19 | 2014-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103182A1 true AR103182A1 (es) | 2017-04-19 |
Family
ID=55071225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104203A AR103182A1 (es) | 2014-12-19 | 2015-12-18 | Inmunomoduladores |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9944678B2 (es) |
| EP (1) | EP3233887B1 (es) |
| JP (1) | JP6705823B2 (es) |
| KR (1) | KR102590776B1 (es) |
| CN (1) | CN107223129B (es) |
| AR (1) | AR103182A1 (es) |
| AU (1) | AU2015364573A1 (es) |
| BR (1) | BR112017012704A2 (es) |
| CA (1) | CA2971266A1 (es) |
| CY (1) | CY1121571T1 (es) |
| DK (1) | DK3233887T3 (es) |
| EA (1) | EA033721B1 (es) |
| ES (1) | ES2719135T3 (es) |
| HR (1) | HRP20190575T1 (es) |
| HU (1) | HUE044027T2 (es) |
| IL (1) | IL252896A0 (es) |
| LT (1) | LT3233887T (es) |
| MX (1) | MX2017008160A (es) |
| PL (1) | PL3233887T3 (es) |
| PT (1) | PT3233887T (es) |
| RS (1) | RS58580B1 (es) |
| SG (1) | SG11201704821VA (es) |
| SI (1) | SI3233887T1 (es) |
| SM (1) | SMT201900253T1 (es) |
| TR (1) | TR201906470T4 (es) |
| TW (1) | TW201629087A (es) |
| WO (1) | WO2016100608A1 (es) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015007051A (es) | 2012-12-07 | 2016-01-12 | Chemocentryx Inc | Diazol lactamas. |
| ES2768610T3 (es) | 2014-09-11 | 2020-06-23 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína PD-1/PD-L1 y CD80(B7-1)/PD-L1 |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| MA42133A (fr) | 2015-05-21 | 2021-06-02 | Chemocentryx Inc | Modulateurs du ccr2 |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| TWI808938B (zh) | 2016-04-07 | 2023-07-21 | 美商卡默森屈有限公司 | 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2017201111A1 (en) | 2016-05-19 | 2017-11-23 | Bristol-Myers Squibb Company | Pet-imaging immunomodulators |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| CN110267971B (zh) * | 2016-11-07 | 2023-12-19 | 百时美施贵宝公司 | 免疫调节剂 |
| IL267572B2 (en) | 2016-12-23 | 2025-02-01 | Univ Johns Hopkins | Tumor and immune cell imaging based on PD-L1 expression |
| US20190336533A1 (en) | 2016-12-28 | 2019-11-07 | Green Cross Lab Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| JP7206222B2 (ja) * | 2017-06-23 | 2023-01-17 | ブリストル-マイヤーズ スクイブ カンパニー | Pd-1のアンタゴニストとして作用する免疫調節剤 |
| BR112020005284A2 (pt) | 2017-09-25 | 2020-09-24 | Chemocentryx, Inc. | terapia de combinação usando um antagonista do receptor de quimiocina 2 (ccr2) e um inibidor de pd-1/pd-l1 |
| WO2019070643A1 (en) * | 2017-10-03 | 2019-04-11 | Bristol-Myers Squibb Company | IMMUNOMODULATORS |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| EP3712178A4 (en) | 2017-11-14 | 2021-08-11 | Green Cross Lab Cell Corporation | ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
| IL275898B2 (en) | 2018-01-08 | 2025-05-01 | Chemocentryx Inc | Methods for treating solid tumors with CCR2 antagonists |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| AU2019277632A1 (en) | 2018-05-31 | 2020-12-24 | National Cancer Center Japan | Biomarker for judging efficacy of immune checkpoint inhibitor |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| TW202446772A (zh) | 2018-10-11 | 2024-12-01 | 日商小野藥品工業股份有限公司 | Sting促效化合物 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US20220195046A1 (en) | 2019-03-28 | 2022-06-23 | Bristol-Myers Squibb Company | Methods of treating tumor |
| CN113677402A (zh) | 2019-03-28 | 2021-11-19 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| KR20220010535A (ko) * | 2019-05-21 | 2022-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| JP7662156B2 (ja) | 2019-08-05 | 2025-04-15 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN114450028A (zh) | 2019-09-22 | 2022-05-06 | 百时美施贵宝公司 | Lag-3拮抗剂治疗的定量空间剖析 |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| US12404299B2 (en) | 2019-11-07 | 2025-09-02 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide compound comprising highly sterically hindered amino acid |
| CA3159931A1 (en) * | 2019-11-07 | 2021-05-14 | Chugai Seiyaku Kabushiki Kaisha | Cyclic peptide compound having kras inhibitory action |
| JP2022553851A (ja) | 2019-11-08 | 2022-12-26 | ブリストル-マイヤーズ スクイブ カンパニー | 黒色腫の処置のためのlag-3アンタゴニスト |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| US12403174B2 (en) | 2020-01-06 | 2025-09-02 | Bristol-Myers Squibb Company | Immunomodulators |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| KR20220161407A (ko) | 2020-03-30 | 2022-12-06 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| WO2021205631A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | Sting作動化合物 |
| US20230141284A1 (en) | 2020-04-10 | 2023-05-11 | Ono Pharmaceutical Co., Ltd. | Cancer therapeutic method |
| CN113754736A (zh) * | 2020-06-02 | 2021-12-07 | 南京礼威生物医药有限公司 | 含酰肼结构的pd-l1环肽抑制剂 |
| AU2021331476A1 (en) | 2020-08-28 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022066635A1 (en) | 2020-09-22 | 2022-03-31 | Avidea Technologies, Inc. | Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ |
| MX2023004493A (es) | 2020-10-23 | 2023-05-10 | Bristol Myers Squibb Co | Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon. |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022212400A1 (en) | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| AR125800A1 (es) | 2021-05-07 | 2023-08-16 | Chugai Pharmaceutical Co Ltd | Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n |
| AU2022270499A1 (en) * | 2021-05-07 | 2023-11-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical use of cyclic peptide compound |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | TLR8調節化合物と抗HBV siRNA治療薬との組合せ |
| JP2024520801A (ja) | 2021-06-11 | 2024-05-24 | ギリアード サイエンシーズ, インコーポレイテッド | Mcl-1阻害剤と抗がん剤との組み合わせ |
| CA3222752A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| JP2025503962A (ja) | 2022-01-26 | 2025-02-06 | ブリストル-マイヤーズ スクイブ カンパニー | 肝細胞がんのための併用療法 |
| US20230326022A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures |
| IL318949A (en) | 2022-08-23 | 2025-04-01 | Ono Pharmaceutical Co | Bispecific antibody |
| KR20250123912A (ko) | 2022-12-21 | 2025-08-18 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 병용 요법 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025193572A1 (en) * | 2024-03-11 | 2025-09-18 | Bristol-Myers Squibb Company | Macrocyclic peptides useful as immunomodulators |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP3012265B1 (en) | 2007-03-26 | 2017-06-28 | The University of Tokyo | Process for synthesizing cyclic peptide compound |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2328919A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| EP2647720B1 (en) | 2010-12-03 | 2019-06-19 | The University of Tokyo | Peptide library production method, peptide library, and screening method |
| EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| EP2822957A1 (en) * | 2012-03-07 | 2015-01-14 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| AU2013239366A1 (en) | 2012-03-29 | 2014-10-16 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the BC loop of human PD1 |
| MX355396B (es) | 2012-06-06 | 2018-04-18 | Polyphor Ag | Peptido - mimeticos de la horquilla beta. |
| WO2013182662A1 (en) * | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Vaccine |
| JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | pH依存的に標的分子に結合するペプチドのスクリーニング方法 |
| US9308236B2 (en) * | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| AU2014235453A1 (en) | 2013-03-15 | 2015-10-08 | Genentech, Inc. | Biomarkers and methods of treating PD-1 and PD-L1 related conditions |
| CA2922982A1 (en) | 2013-09-06 | 2015-03-12 | Aurigene Discovery Technologies Limited | Cyclic peptidomimetic compounds as immunomodulators |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| ES2768610T3 (es) | 2014-09-11 | 2020-06-23 | Bristol Myers Squibb Co | Inhibidores macrocíclicos de las interacciones proteína/proteína PD-1/PD-L1 y CD80(B7-1)/PD-L1 |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) * | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
-
2015
- 2015-12-16 US US14/971,352 patent/US9944678B2/en active Active
- 2015-12-17 SI SI201530635T patent/SI3233887T1/sl unknown
- 2015-12-17 AU AU2015364573A patent/AU2015364573A1/en not_active Abandoned
- 2015-12-17 RS RS20190419A patent/RS58580B1/sr unknown
- 2015-12-17 SG SG11201704821VA patent/SG11201704821VA/en unknown
- 2015-12-17 DK DK15820775.3T patent/DK3233887T3/da active
- 2015-12-17 JP JP2017532680A patent/JP6705823B2/ja active Active
- 2015-12-17 MX MX2017008160A patent/MX2017008160A/es unknown
- 2015-12-17 EA EA201791216A patent/EA033721B1/ru not_active IP Right Cessation
- 2015-12-17 TR TR2019/06470T patent/TR201906470T4/tr unknown
- 2015-12-17 CA CA2971266A patent/CA2971266A1/en not_active Abandoned
- 2015-12-17 PL PL15820775T patent/PL3233887T3/pl unknown
- 2015-12-17 PT PT15820775T patent/PT3233887T/pt unknown
- 2015-12-17 CN CN201580075897.7A patent/CN107223129B/zh active Active
- 2015-12-17 SM SM20190253T patent/SMT201900253T1/it unknown
- 2015-12-17 WO PCT/US2015/066272 patent/WO2016100608A1/en not_active Ceased
- 2015-12-17 EP EP15820775.3A patent/EP3233887B1/en active Active
- 2015-12-17 HR HRP20190575TT patent/HRP20190575T1/hr unknown
- 2015-12-17 HU HUE15820775A patent/HUE044027T2/hu unknown
- 2015-12-17 KR KR1020177019584A patent/KR102590776B1/ko active Active
- 2015-12-17 ES ES15820775T patent/ES2719135T3/es active Active
- 2015-12-17 BR BR112017012704-0A patent/BR112017012704A2/pt not_active Application Discontinuation
- 2015-12-17 LT LTEP15820775.3T patent/LT3233887T/lt unknown
- 2015-12-18 AR ARP150104203A patent/AR103182A1/es unknown
- 2015-12-18 TW TW104142843A patent/TW201629087A/zh unknown
-
2017
- 2017-06-14 IL IL252896A patent/IL252896A0/en unknown
-
2019
- 2019-04-25 CY CY20191100451T patent/CY1121571T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9944678B2 (en) | 2018-04-17 |
| US20160176928A1 (en) | 2016-06-23 |
| EP3233887A1 (en) | 2017-10-25 |
| CA2971266A1 (en) | 2016-06-23 |
| JP2018504378A (ja) | 2018-02-15 |
| TW201629087A (zh) | 2016-08-16 |
| PL3233887T3 (pl) | 2019-08-30 |
| KR102590776B1 (ko) | 2023-10-18 |
| MX2017008160A (es) | 2017-09-18 |
| AU2015364573A1 (en) | 2017-08-03 |
| HUE044027T2 (hu) | 2019-09-30 |
| CN107223129A (zh) | 2017-09-29 |
| LT3233887T (lt) | 2019-04-25 |
| BR112017012704A2 (pt) | 2018-03-06 |
| IL252896A0 (en) | 2017-08-31 |
| ES2719135T3 (es) | 2019-07-08 |
| SI3233887T1 (sl) | 2019-04-30 |
| RS58580B1 (sr) | 2019-05-31 |
| CN107223129B (zh) | 2022-01-04 |
| JP6705823B2 (ja) | 2020-06-03 |
| PT3233887T (pt) | 2019-04-30 |
| DK3233887T3 (da) | 2019-05-13 |
| KR20170098872A (ko) | 2017-08-30 |
| EP3233887B1 (en) | 2019-02-06 |
| EA033721B1 (ru) | 2019-11-20 |
| SMT201900253T1 (it) | 2019-07-11 |
| EA201791216A1 (ru) | 2017-10-31 |
| HRP20190575T1 (hr) | 2019-05-17 |
| CY1121571T1 (el) | 2020-05-29 |
| WO2016100608A1 (en) | 2016-06-23 |
| TR201906470T4 (tr) | 2019-05-21 |
| SG11201704821VA (en) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103182A1 (es) | Inmunomoduladores | |
| AR103093A1 (es) | Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1 | |
| AR107802A1 (es) | Inmunomoduladores | |
| AR103969A1 (es) | Inmunomoduladores | |
| AR108186A1 (es) | Péptidos macrocíclicos que inhiben las interacciones proteína / proteína, proteína de muerte programada 1 (pd-1) / ligando de pd-1 (pd-l1) y pd-l1 / cd80 | |
| AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
| AR124117A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
| AR099824A1 (es) | Compuestos bicíclicos | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR099023A1 (es) | Pirazolil-heteroarilamidas como agentes plaguicidas | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR088328A1 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes | |
| AR092347A1 (es) | Derivados de azaindol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |